Gülmez Dolunay, Woodford Neil, Palepou Marie-France I, Mushtaq Shazad, Metan Gokhan, Yakupogullari Yusuf, Kocagoz Sesin, Uzun Omrum, Hascelik Gulsen, Livermore David M
Hacettepe University Faculty of Medicine, Department of Microbiology and Clinical Microbiology, 06100 Sihhiye, Ankara, Turkey.
Int J Antimicrob Agents. 2008 Jun;31(6):523-6. doi: 10.1016/j.ijantimicag.2008.01.017. Epub 2008 Mar 12.
Treatment options are limited in infections caused by extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae, with carbapenems generally preferred. Disturbingly, however, carbapenem-resistant strains are emerging worldwide. Here we report two clinical isolates, one Escherichia coli and one Klebsiella pneumoniae, each with high-level carbapenem resistance (imipenem minimum inhibitory concentration of 32 microg/mL). They were isolated following imipenem therapy from two hospital patients who had received imipenem therapy in different regions of Turkey. Both isolates produced OXA-48-like carbapenemases, enzymes so far reported only from Turkey. Both isolates also had group 1 CTX-M-type ESBLs and had lost major outer membrane proteins. OXA-48-like carbapenemases appear to be scattered in Turkey and surveillance to determine their prevalence is warranted.
对于由产超广谱β-内酰胺酶(ESBL)的肠杆菌科细菌引起的感染,治疗选择有限,通常首选碳青霉烯类药物。然而,令人不安的是,耐碳青霉烯类菌株正在全球范围内出现。在此,我们报告两株临床分离株,一株大肠杆菌和一株肺炎克雷伯菌,每株都具有高水平的碳青霉烯类耐药性(亚胺培南最低抑菌浓度为32μg/mL)。它们是在亚胺培南治疗后从两名在土耳其不同地区接受过亚胺培南治疗的医院患者中分离出来的。两株分离株均产生OXA-48样碳青霉烯酶,这种酶迄今为止仅在土耳其有报道。两株分离株还具有1型CTX-M型ESBLs,并且失去了主要外膜蛋白。OXA-48样碳青霉烯酶似乎在土耳其呈散在分布,因此有必要进行监测以确定其流行情况。